These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 22095822)

  • 1. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
    Roy U; Chakravarty G; Honer Zu Bentrup K; Mondal D
    Biol Pharm Bull; 2009 Dec; 32(12):2002-9. PubMed ID: 19952419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning and characterization of the rat multidrug resistance-associated protein 1.
    Yang Z; Li CS; Shen DD; Ho RJ
    AAPS PharmSci; 2002; 4(3):E15. PubMed ID: 12423064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slug Mediates MRP2 Expression in Non-Small Cell Lung Cancer Cells.
    Zhang X; Liu W; Edaki K; Nakazawa Y; Takahashi S; Sunakawa H; Mizoi K; Ogihara T
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism, Transport and Drug-Drug Interactions of Silymarin.
    Xie Y; Zhang D; Zhang J; Yuan J
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31615114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier.
    Arana MR; Tocchetti GN; Rigalli JP; Mottino AD; Villanueva SS
    Pharmacol Res; 2016 Jul; 109():32-44. PubMed ID: 27109321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression.
    Wang S; Feng R; Wang SS; Liu H; Shao C; Li Y; Link F; Munker S; Liebe R; Meyer C; Burgermeister E; Ebert M; Dooley S; Ding H; Weng H
    Gut; 2023 Mar; 72(3):549-559. PubMed ID: 35444014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition.
    Saib S; Delavenne X
    Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of the gut microbiota on the bioavailability of oral drugs.
    Zhang X; Han Y; Huang W; Jin M; Gao Z
    Acta Pharm Sin B; 2021 Jul; 11(7):1789-1812. PubMed ID: 34386321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Mrp2 surface availability as PI3Kγ-mediated hepatocytic dysfunction reflecting a hallmark of cholestasis in sepsis.
    Beer AJ; Hertz D; Seemann E; Beretta M; Westermann M; Bauer R; Bauer M; Kessels MM; Qualmann B
    Sci Rep; 2020 Aug; 10(1):13110. PubMed ID: 32753644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human MRP2 exports MC-LR but not the glutathione conjugate.
    Kaur G; Fahrner R; Wittmann V; Stieger B; Dietrich DR
    Chem Biol Interact; 2019 Sep; 311():108761. PubMed ID: 31348918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of expression and activity of intestinal multidrug resistance-associated protein 2 by xenobiotics.
    Tocchetti GN; Rigalli JP; Arana MR; Villanueva SSM; Mottino AD
    Toxicol Appl Pharmacol; 2016 Jul; 303():45-57. PubMed ID: 27155371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
    Keppler D
    Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter-mediated natural product-drug interactions for the treatment of cardiovascular diseases.
    Zha W
    J Food Drug Anal; 2018 Apr; 26(2S):S32-S44. PubMed ID: 29703385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mrp2 is involved in the efflux and disposition of fosinopril.
    Green BR; Bain LJ
    J Appl Toxicol; 2013 Jun; 33(6):458-65. PubMed ID: 22095822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
    Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.
    Keppler D
    Handb Exp Pharmacol; 2011; (201):299-323. PubMed ID: 21103974
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.